The smaller pharma companies I find it tough to evaluate, so many of them can potentially do well but I do not have the bandwidth to go molecule by molecule and evaluate those companies. But I think Sun Pharma is a decent business model, so we are just holding it for the long term.
Positive Breakout: These 7 stocks cross above their 200 DMAs
In the Nifty 500 pack, seven stocks’ close prices crossed above their 200 DMA (Daily Moving Averages) on June 17, according to stockedge.com’s technical scan
June 18, 2025